News, Infos & good to know WKN: A14XC6 ISIN: US63016Q1022 Kürzel: 26C Forum: Aktien User: Lirumlarum1

Vielleicht gibt es vor der evtl. kommenden Kapitalmaßnahme ja noch Geld aus öffentlichen Töpfen. Joe Biden soll uns mal unter die Arme greifen. Die Töpfe sowohl für die Covidforschung, als auch für das Cancer breakthrough wurden erheblich aufgestockt. Biden still pushing for his cancer 'breakthrough' dream, but can it work? https://www.fiercebiotech.com/biotech/president-biden-still-pushing-for-his-cancer-breakthrough-dream-but-can-it-work

Nantkwest and ImmunityBio start dosing in global COVID-19 vaccine trials Mar. 08, 2021 11:28 AM ETNantKwest, Inc. (NK)By: Aakash Babu, SA News Editor6 Comments NantKwest (NASDAQ:NK) and privately-held ImmunityBio announce that the first cohorts of their South Africa and U.S. COVID-19 vaccine trials have received their initial doses of the T-cell-based COVID-19 vaccine candidate, hAd5. The trials aim to determine which route combination provides the strongest immune response and long-term immunity, as well as the vaccine candidate’s effectiveness against the growing number of mutated variants of the virus. In the three trials, the hAd5 vaccine candidate is being administered in a subcutaneous, oral, or sublingual formulation.  In total, 140 participants will be enrolled in the South African and U.S. trials. NantKwest entered into a reverse merger agreement with ImmunityBio to create an immunotherapy and cell therapy company focused on oncology and infectious disease, in December last year. https://seekingalpha.com/news/3670319-nantkwest-and-immunitybio-start-dosing-in-global-covid-19-vaccine-trials?utm_source=feed_news_all&utm_medium=referral

Merger approved! The merger is expected to close on March 9, 2021, subject to the satisfaction of customary closing conditions. Following the closing of the transaction, the combined company will assume the ImmunityBio name and its shares of common stock are expected to trade on NASDAQ under the symbol “IBRX” commencing on March 10, 2021. https://ir.nantkwest.com/news-releases/news-release-details/stockholders-nantkwest-approve-merger-immunitybio

South Africa develops African-made Covid-19 vaccines Africa’s innovation that knows no bounds has seen new Covid-19 vaccines being refined in South Africa with the potential to outsmart current and future variants – strengthening the fight against the pandemic. The new covid-19 vaccines, Shantivax and had5 are considered to be the next-generation Covid-19 vaccines. Gqeberha (formerly Port Elizabeth) based immunotherapy company, and Danish biotechnology company, Immunitrack, are behind Shantivax – the first Covid-19 vaccine of African origin. The had5 Covid-19 vaccine was designed by Immunitybio Inc, an immunotherapy company from California with a lineage in cancer treatments, along with researchers from the University of Cape Town. Most of the current Covid-19 vaccines trigger an immune response resulting in antibodies but both the Shantivax and had5 vaccines aim to additionally elicit a T-cell immune response. A T-cell response is meant to destroy the virus. Professor Barry Schoub, virologist and chair of the ministerial advisory committee on Covid-19 vaccines, explained that the immune system had two branches. “There is B-cell immunity which produces antibodies and T-cell immunity which governs recovery from infection but also protection as it prevents the virus from multiplying in cells that get infected. The current concern is that variants can escape neutralising antibody responses so a joint B-cell and T-cell response create a wider net that can be cast over a wider range of current and future variants as the result of a multi-layered immune response. A supplementary T-cell booster could go part and parcel with current vaccines as a possible way forward.” Immunitybio chief executive Patrick Soon-shiong said results had been promising and discussions were underway for their vaccine to be integrated into the Sisonke Programme that currently rolled out the Johnson & Johnson vaccine. “Time is of the essence, at great personal expense we have given ourselves the manufacturing capacity to produce millions of these capsule supplements derived from our vaccine that trigger a T-cell response. They can be kept at room temperature, taken orally and transported with less hassle than current vaccines. In primate studies, those that received the boost showed transmission immunity in the nose and lungs plus the virus stopped growing. All we need is the go-ahead from the powers that be,” he said. Soon-shiong was born in Gqeberha and said he made a personal promise to return to the country with resources and technology. “I think the country’s scientists and the current infrastructure is some of the best and most sophisticated in the world, that is why I brought our vaccine to the country. I still consider myself a South African and believe we have the human capital but capacity needs to increase and that is where I want to help the nation grow.” Professor Graeme Meintjes from the University of Cape Town along with his team oversaw the local branch of the had5 vaccine. “We have been planning this clinical trial since July. They approached us to conduct clinical development of the vaccine in parallel with the US. There are 25 team members including doctors, nurses, pharmacists, counsellors, a community team and administrators who are led by myself as clinical research site leader and Amy Ward the principal trial investigator,” he said. Meintjes said Cape Town’s Biovac Institute was collaborating on the trial and locally stored the test products but the long-term plan was that they would be involved in locally manufacturing. Morena Makhoana, chief executive of the Biovac Institute, confirmed active discussions were had with global pharmaceutical companies regarding local manufacturing and production of Covid-19 vaccines but was unable to disclose the nature of these discussions. The South African Health Products Regulatory Authority’s (SAHPRA) Yuven Gounden said an application to conduct clinical trials for the had5 T-cell vaccine was received in the last quarter of 2020 and approval was granted on January 12. Kamsellin Chetty, chief executive of GENLAB, said Shantivax was still in the preclinical testing phase. “Simply put we are in pre-human testing. SAHPRA only checks clinical or human testing but we submit our scientific data for approval and follow strict ethical scientific guidelines to ensure efficacy and maximum safety. We are a next-generation vaccine which means we have learnt from the mistakes of others and evolved to be better. We adapted to mitigate the emergence of variants,” he said.

https://amp.theage.com.au/world/europe/game-changing-covid-19-vaccine-pill-pursued-by-small-british-firm-world-s-richest-doctor-20210301-p576wl.html?btis=&__twitter_impression=true

https://t..co/m3h97kELYO?amp=1 Mit nur einem Punkt zwischen t und co

NantKwest @NantKwest 6. März Temperature-controlled vaccines have presented their own challenges, but what if we were able to provide a longer-lasting immune response and overcome the need for temperature-regulated storage? Learn more: https://t.co/m3h97kELYO?amp=1

Nantkwest on Twitter: Patrick Soon-Shiong, Executive Chairman of ImmunityBio & NantKwest, has emerged as a powerful force behind vaccines. His goal is to protect people from infection caused by variants of coronavirus - now & in the future.

Game-changing COVID-19 vaccine pill pursued by small British firm, world’s richest doctor https://www.smh.com.au/world/europe/game-changing-covid-19-vaccine-pill-pursued-by-small-british-firm-world-s-richest-doctor-20210301-p576wl.html#comments

bit. ly

ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors About John Brennan Mr. Brennan served for 25 years in a variety of roles at the CIA, rising from analyst to station chief, and finally being appointed as the agency’s Director by President Barack Obama. He also served as Deputy National Security Advisor for Homeland Security and Counterterrorism. Brennan earned a Bachelor of Arts degree from Fordham University, and is a Distinguished Fellow at the Fordham University Law School. He earned a Master of Arts from the University of Texas at Austin, where he currently serves as a Distinguished Non-Resident Scholar and a senior advisor to the University’s Intelligence Studies Projects. About Wesley Clark General Clark served for 34 years in the U.S. Army, rising through the ranks to earn his fourth star as a full general in 1996. He served as the Supreme Allied Commander Europe of NATO where he commanded Operation Allied Force in the Kosovo War. Highly decorated throughout his career, Gen. Clark was awarded the U.S. Presidential Medal of Freedom by President Bill Clinton. He is a graduate of the U.S. Military Academy at West Point, where he was class valedictorian. After graduating from West Point, General Clark was awarded a Rhodes Scholarship to the University of Oxford where he earned degrees in Philosophy, Politics and Economics. He earned a master’s degree in military science from the Command and General Staff College. General runs Wesley K. Clark and Associates consulting firm and is Chairman and CEO of Enverra, a boutique investment bank. Der ganze Artikel auf: https://www.businesswire.com/news/home/20210224005400/en/ImmunityBio-Appoints-John-Brennan-and-Wesley-Clark-to-Board-of-Directors

Jim Cramer spoke on CNBC's "Mad Money Lightning Round" about Nantkwest Inc (NASDAQ: NK). He said it is a great immunotherapy company. It is a spec but he is fine with that.

SA billionaire behind ‘vaccine breakthrough’ https://www.iol.co.za/business-report/companies/sa-billionaire-behind-vaccine-breakthrough-4f6ff207-7038-4c17-a50a-4d7f02f97582

Link zum HIV Programm mit dem Militär: Ab Seite 222: https://ir.nantkwest.com/node/8461/html

IB und NK - Pipeline: Krebs: -Lungenkrebs -Blasenkrebs -Brustkrebs -Bauchspeicheldrüsenkrebs -Glioblastom -Merkel Zellkarzinom -Dickdarmkrebs -Stachelzellkrebs -Flüssige und Feste Tumore im. Allgemeinen -Zell Lymphome Allgemein: -Antikörper -Zytokine -Fusionsproteine Ansteckende Krankheiten: -Covid-19 -HIV